EU
Market Access/ News/ News/ News/ Oncology
AZ’s Imfinzi/Imjudo combo backed in EU for liver, lung cancers
Phil Taylor
AstraZeneca, CHMP, Enhertu, EU, Imfinzi, Imjudo, immuno-oncology, Oncology
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
CSL closes on EU approval for haemophilia B gene therapy
Phil Taylor
CHMP, CSL, EU, gene therapy, haemophilia B, Hemgenix, uniQure
0 Comment
Digital/ News/ News/ News/ Oncology
EU launches AI-powered real-world data project for cancer therapies
Phil Taylor
digital, digital health, EU, Health Technology Assessment, HEOR, Horizon Europe programme, Oncology
0 Comment
EMA unveils first projects as data partners join DARWIN EU project
Phil Taylor
big data, DARWIN, digital, digital health, ema, EU, real world data, Real World Evidence
0 Comment
Cancer/ Events/ Insights/ Oncology/ Views and analysis/ World Cancer Series
Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)
Nicole Raleigh
BECA, cancer care, Cancer Research UK, Economist Impact, EU, Government of Malta, Innovation, MSD Italy, prevention, The Economist, World Cancer Series
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
AstraZeneca’s Tezspire for severe asthma gets green light in EU
Phil Taylor
Amgen, asthma, AstraZeneca, EU, regulatory approval, severe asthma, Tezspire
0 Comment
Otsuka, Aurinia claim EU okay for oral lupus nephritis drug
Phil Taylor
Aurinia, EU, Lupkynis, lupus, lupus nephritis, Otsuka, regulatory approval
0 Comment
News/ News/ Sales and Marketing
Novartis probed by Swiss authorities over ‘unlawful’ patent use
Phil Taylor
antitrust, EU, Financial, Novartis, patent, regulatory, switzerland
0 Comment